Payal D. Shah

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-152
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-349-5730
Fax: 215-615-3349
Education:
BA (Bachelor of Arts in Biological Sciences, Magna Cum Laude)
Columbia College, Columbia University , 2004.
MD (Doctor of Medicine )
Perelman School of Medicine, University of Pennsylvania , 2009.
Permanent link
 

Description of Itmat Expertise

Cancer genetics, breast cancer, ovarian cancer, cardio-oncology

Description of Other Expertise

Dr. Payal D. Shah is an Assistant Professor of Medicine in the Division of Hematology / Oncology at the University of Pennsylvania. She is a medical oncologist and clinical investigator who specializes in breast cancer, ovarian cancer, and cancer genetics. With the support of the Basser Center for BRCA, Dr. Shah’s research focus is on novel therapeutics, including targeted therapy and immunotherapy, for patients with breast and ovarian cancer.

Selected Publications

D Finkelman BS, Putt M, Wang T, Wang L, Narayan H, Domchek S, DeMichele A, Fox K, Matro J, Shah P, Clark A, Bradbury A, Narayan V, Carver J, Wilson Tang WH, Ky B.: Early changes in arginine-nitric oxide metabolites and subsequent cardiac dysfunction in breast cancer patients. Journal of the American College of Cardiology. 70(2): 152-162, July 2017.

Shah PD, Digiovanni L, Maxwell KN, Bradbury AR, Van Den Akker J, Kim S, Gil E, Simon MS, Nathanson KL, Domchek SM: Spectrum of hereditary breast and ovarian cancer gene variants in an African American cohort SABCS 2016 Dec 2016.

Hamdi Y, Soucy P, Kuchenbaeker KB, Pastinen T, Droit A, Lemaçon A, et al.: Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment Oct 2016 Notes: [Epub ahead of print]

Shah PD, Patil S, Dickler MN, Offit K, Hudis CA, Robson ME.: Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status. Cancer 122(8): 1178-84, Apr 2016.

Shah PD, Moynahan ME, Modi S, Hamilton N, Caravella B, Zamora S, Dang C, Gilewski T, Traina T, Comen E, Sugarman S, D’Andrea G, Lake D, Goldfarb S, Patil S, Covey A, Berger M, Lacouture M, Norton L, Hudis C, Baselga J, Chandarlapaty S, Dickler M.: Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT330. doi:10.1158/1538-7445.AM2015-CT330. Oral Presentation 2015.

Shah PD, Chandarlapaty S, Dickler M, Ulaner G, Zamora S, Sterlin V, Iasonos A, Coughlin C, Morozov A, Ero J, Rosen N, Gilewski T, Fornier M, Sklarin N, Berger M, Moynahan M, Hudis C, Baselga J, Modi S.: Phase I study of LJM716, BYL719 and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer. J Clin Oncol 33, 2015 (suppl; abstr 590). Poster, ASCO Annual Meeting 2015.

Shah PD, Patil S, Dickler M, Offit K, Hudis C, Robson M.: Oncotype DX in BRCA-associated vs. sporadic breast cancers: differences based on germline mutation status and potential implications for adjuvant systemic therapy. J Clin Oncol 33, 2015 (suppl; abstr 519). Poster discussion, ASCO Annual Meeting 2015.

Shah PD, Moynahan ME, Modi S, Caravella B, Datko F, Zamora S, Comen E, Gilewski T, Sugarman S, D'Andrea G, Lake D, Goldfarb S, Patil S, Covey A, Berger M, Lacouture M, Norton L, Hudis C, Baselga J, Chandarlapaty S, Dickler M.: Phase I trial: P13Ka inhibitor BYL719 plus aromatase inhibitor (AI)for patients with hormone receptor-postive (HR+)metastatic breast cancer (MBC): Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr PD5-3. Dec 2014 Notes: Poster discussion.

Shah PD, Chandarlapaty S, Ulaner G, Zamora S, Sterlin V, Iasonos A, Dickler M, Moynahan ME, Hudis C, Baselga J, Modi S. : Ongoing Trials: Phase I, open-label study evaluating the safety and tolerability of LJM716, BYL719 and trastuzumab in patients with metastatic HER2+ breast cancer: Abstract 780. Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr PD5-3. Dec 2014.

Shah PD, Dickler MN.: Endocrine therapy for advanced breast cancer. Clinical Advances in Hematology Oncology. 12(4): 214-223, Apr 2014.

back to top
Last updated: 10/27/2017
The Trustees of the University of Pennsylvania